Stockscreener 앱 받기
62.20
3.98%
2.38
시간 외 거래:
62.20
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
What downside risks could hit Cytokinetics Incorporated (KK3A) stockWeekly Trend Report & Technical Pattern Recognition Alerts - Улправда
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Goldman Sachs upgrades Cytokinetics stock rating to Buy on HCM drug potential - Investing.com
Is Cytokinetics Incorporated (KK3A) stock a top pick for value investorsTrade Volume Report & Free Community Consensus Stock Picks - Улправда
China approves Cytokinetics’ heart drug MYQORZO, triggering $7.5m payment - Investing.com Nigeria
Why Cytokinetics Incorporated stock is favored by top institutionsJuly 2025 Institutional & Capital Efficient Trading Techniques - Bollywood Helpline
On cusp of FDA and European decisions, Cytokinetics heart drug wins approval in China - The Business Journals
Cytokinetics' Hypertrophic Cardiomyopathy Treatment Approved in China - marketscreener.com
Cytokinetics rises after winning China approval for heart disease drug - TradingView — Track All Markets
Cytokinetics Wins China Approval For Myqorzo In Obstructive Hypertrophic Cardiomyopathy - Nasdaq
Cytokinetics (CYTK) Gains Approval for MYQORZO in China, Unlocks Milestone Payment - GuruFocus
Cytokinetics announces NMPA approval of Myqorzo® in China - marketscreener.com
Mirador Capital Partners LP Acquires 53,020 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Announces Nmpa Approval Of Myqorzo® In China - TradingView — Track All Markets
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy - The Manila Times
New heart drug in China approved to ease obstructive cardiomyopathy symptoms - Stock Titan
Sanders Morris Harris LLC Takes $1.18 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Insider Sell: Fady Malik Sells 2,200 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Frazier Life Sciences Management L.P. Invests $18.33 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Regeneron (REGN) - The Globe and Mail
Needham & Company LLC Reaffirms "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
EMA’s CHMP backs new medicines from Hansoh, Cytokinetics - biocentury.com
Cytokinetics receives positive EU opinion for MYQORZO in heart condition By Investing.com - Investing.com Canada
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ... - Bakersfield.com
CHMP recommends Immunitybio's Anktiva, Cytokinetics' Myqorzo - BioWorld MedTech
Cytokinetics Receives CHMP's Positive Opinion On MYQORZO - Nasdaq
EMA committee recommends approval of Cytokinetics’ oHCM drug - Investing.com
Cytokinetics (CYTK) Receives Positive EU Recommendation for MYQO - GuruFocus
EMA committee recommends approval of Cytokinetics’ oHCM drug By Investing.com - Investing.com Australia
Cytokinetics receives positive EU opinion for MYQORZO in heart condition - Investing.com
Cytokinetics Receives Positive Opinion for MYQORZO® in EU - TradingView — Track All Markets
Cytokinetics Announces Positive CHMP Opinion Of MYQORZO For The Treatment Of Obstructive Hypertrophic Cardiomyopathy - TradingView — Track All Markets
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® - GlobeNewswire
Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026 - Stock Titan
Cytokinetics (CYTK) Stock Rating Reiterated at 'Buy' by Needham - GuruFocus
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Notice For Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire
Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $68,730 in shares - Investing.com
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares - sharewise.com
Norges Bank Invests $39.12 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Bought by CW Advisors LLC - MarketBeat
Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Shareholder Probe Into FDA Disclosures Reshaping the Investment Case for Cytokinetics’ Aficamten Story (CYTK)? - simplywall.st
Brown Advisory Inc. Has $32.89 Million Stake in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock - MarketBeat
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock By Investing.com - Investing.com South Africa
Insider Sell: Andrew Callos Sells 52,486 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos Andrew, Cytokinetics EVP, sells $3.46m in stock - Investing.com India
Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - sharewise.com
Will Cytokinetics Incorporated (KK3A) stock issue positive guidanceJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Can Cytokinetics Incorporated (KK3A) stock double in coming years2025 Earnings Impact & Weekly Market Pulse Updates - Newser
0.31%
0.33%
자본화:
|
볼륨(24시간):